The Global anti-venom market is estimated to be valued at US$ 1,270.1 Mn in 2024 and is expected to exhibit a CAGR of 8.6% over the forecast period 2024 To 2031.

Key Takeaways
Key players operating in the anti-venom market are Bharat Serums and Vaccines Limited, Haffkine Bio-Pharmaceutical Corporation Ltd, Vins Bioproducts Limited, Incepta Pharmaceuticals, Rare Disease Therapeutics.
Key opportunities in the market include developing anti-venoms for highly venomous species and setting up indigenous production facilities in regions with high incidence of bites.
Recent advancements in venom extraction technologies allows for higher and purer yields of venom, enabling development of broad-spectrum anti-venoms. New technologies like recombinants and fragments are being explored to develop effective and affordable treatment options.

Market Drivers
Rising cases of snake bites, scorpion stings and other envenomations globally due to increasing human expansion and environmental changes is a major driver for the Anti Venom Market Demand. As per WHO, there are an estimated 5.4 million snakebites annually resulting in 2.7 million envenomings and around 138,000 deaths. Thus, increasing healthcare expenditure and awareness about treatment is propelling market growth.

Current challenges in Anti-Venom Market
Anti-venom production faces many challenges due to complex nature of venom proteins and antibodies against them. Ensuring high purity, safety and efficacy of anti-venoms is difficult. Short shelf life of 6–12 months requires efficient cold chain logistics. Limited availability of venom for production and higher costs of meeting regulatory standards increase treatment costs. Lack of standardized treatment practices and inadequate healthcare infrastructure in many regions contribute to high mortality rates.

Get more insights on Anti Venom Market